Keyword: Aspen Pharmacare

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Cambrex will have a new U.S. facility capable of producing high-potency APIs ready and running in May.

Aspen Pharmacare says it will invest nearly $235 million in a facility to manufacture sterile anesthetics.

Aspen Pharmacare is expanding into complex meds for cancer and other conditions and has opened an $80 million facility that can produce them.

Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.

European antitrust regulators are looking into Aspen Pharmacare's price hikes on a handful of cancer meds.

Over 7 years, GlaxoSmithKline’s investment in Aspen Pharmacare grew in value sixfold. But that run has come to an end, as GSK wrapped up its final stake sale in the South African company Thursday, raising about $620 million.

AstraZeneca is once again trading off old meds for new money. The U.K.-based pharma off-loaded an anesthetics portfolio to Aspen Pharmacare for up to $770 million, the latest in a string of cash-generating deals.